دورية أكاديمية
Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
| العنوان: | Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. |
|---|---|
| المؤلفون: | Garcia-Marco JA; Hospital Universitario Puerta de Hierro, Madrid, Spain. jagarciam@aehh.org, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA |
| المصدر: | Cancer [Cancer] 2009 May 01; Vol. 115 (9), pp. 1892-8. |
| نوع المنشور: | Evaluation Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Print ISSN: 0008-543X (Print) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
| مواضيع طبية MeSH: | Liposomes*, Cytarabine/*therapeutic use , Lymphoma/*drug therapy , Lymphoma/*pathology , Meningeal Carcinomatosis/*drug therapy , Meningeal Carcinomatosis/*secondary, Adult ; Aged ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Drug Evaluation ; Female ; Humans ; Injections, Spinal ; Male ; Middle Aged ; Quality of Life ; Retrospective Studies |
| مستخلص: | Background: : Standard intrathecal chemotherapy for lymphomatous meningitis (LM) is limited by the short cerebrospinal half-lives of the agents used, necessitating frequent administration. Liposomal cytarabine (DepoCyte) has an extended half-life that permits administration at 2- to 4-weekly intervals. Methods: : Patients with LM who underwent treatment with liposomal cytarabine at treatment centers in Spain between 2004 and 2007 were identified. Data on demographics, treatment, and outcomes were extracted from medical notes and entered, retrospectively, into a database for analysis. Results: : Data on 55 patients with lymphoma (mainly stage IV) and LM were entered into the database. Most patients (n = 36) had diffuse large B-cell lymphoma. The median number of cycles of liposomal cytarabine received was 4 (range, 1-10), and the median follow-up period was 124 days. Complete and partial neurologic responses were achieved in 27 and 12 patients, respectively (overall response rate, 72%), all of whom also showed a cytological response, except for 5 with initially negative cytology. Median time to neurologic progression among responders was 105.5 days. Liposomal cytarabine was generally well tolerated; headache was the most commonly reported adverse effect (n = 17). Conclusions: : Liposomal cytarabine is effective and well tolerated in the treatment of LM, and should be considered as an agent of choice for the treatment of this complication. Cancer 2009. (c) 2009 American Cancer Society. |
| المشرفين على المادة: | 0 (Liposomes) 04079A1RDZ (Cytarabine) |
| تواريخ الأحداث: | Date Created: 20090224 Date Completed: 20090616 Latest Revision: 20191210 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1002/cncr.24204 |
| PMID: | 19235254 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0008-543X |
|---|---|
| DOI: | 10.1002/cncr.24204 |